+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07607964

Study of ABBV-519 to Evaluate Safety and How the Drug Works in Adults With Systemic Lupus Erythematosus or Rheumatoid Arthritis Receiving a Single Dose

Led by AbbVie · Updated on 2026-10-20

30

Participants Needed

15

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of ABBV-519 in adults with Systemic Lupus Erythematosus SLE or Rheumatoid Arthritis RA, two chronic autoimmune diseases. This phase 1 trial aims to understand how ABBV-519 moves through the body, its safety, and its effects on immune cells in people with moderate SLE or RA. The study is led by AbbVie and involves about 30 participants. Participants will receive a single dose of ABBV-519 either as an intravenous IV infusion or a subcutaneous SC injection. The study is designed as a single ascending dose trial with multiple dosing groups. The total study period spans approximately 425 days, including a 60-day screening period, a 1-day treatment administration, and a 52-week follow-up after dosing. Throughout the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor treatment effects and potential side effects. Researchers will measure changes in blood B cell counts and pharmacokinetic parameters such as drug concentration over time. Safety will be closely monitored for adverse events during the entire study period.

CONDITIONS

Brief Title

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here